Healthcare provider profile · identity verified

Ferdinand Tan, MD

Internal Medicine · LAS VEGAS, NV · NPI 1265479034

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	809	262
Amlodipine Besylate	Amlodipine Besylate	480	156
Losartan Potassium	Losartan Potassium	419	133
Metformin Hcl	Metformin Hcl	301	87
Levothyroxine Sodium	Levothyroxine Sodium	220	64
Lisinopril	Lisinopril	192	57
Metoprolol Tartrate	Metoprolol Tartrate	151	43
Allopurinol	Allopurinol	136	44
Rosuvastatin Calcium	Rosuvastatin Calcium	133	46
Tamsulosin Hcl	Tamsulosin Hcl	130	42
Metformin Hcl Er	Metformin Hcl	110	39
Ozempic	Semaglutide	107	23
Pantoprazole Sodium	Pantoprazole Sodium	107	35
Gabapentin	Gabapentin	102	31
Jardiance	Empagliflozin	101	23
Alendronate Sodium	Alendronate Sodium	100	31
Metoprolol Succinate	Metoprolol Succinate	100	35
Omeprazole	Omeprazole	99	32
Irbesartan	Irbesartan	94	26
Albuterol Sulfate Hfa	Albuterol Sulfate	88	30
Simvastatin	Simvastatin	87	31
Hydrochlorothiazide	Hydrochlorothiazide	86	28
Pravastatin Sodium	Pravastatin Sodium	71	23
Eliquis	Apixaban	64	21
Fluticasone Propionate	Fluticasone Propionate	62	23
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	60	21
Glimepiride	Glimepiride	58	17
Trazodone Hcl	Trazodone Hcl	56	23
Clopidogrel	Clopidogrel Bisulfate	55	16
Hydroxyzine Hcl	Hydroxyzine Hcl	55	17
Atenolol	Atenolol	53	18
Furosemide	Furosemide	53	15
Carvedilol	Carvedilol	51	19
Triamcinolone Acetonide	Triamcinolone Acetonide	49	24
Sildenafil Citrate	Sildenafil Citrate	47	suppressed
Trulicity	Dulaglutide	44	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	42	13
Finasteride	Finasteride	42	13
Zolpidem Tartrate	Zolpidem Tartrate	41	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	37	12
Farxiga	Dapagliflozin Propanediol	36	suppressed
Fenofibrate	Fenofibrate	36	12
Potassium Chloride	Potassium Chloride	33	13
Glipizide	Glipizide	32	suppressed
Propranolol Hcl	Propranolol Hcl	32	suppressed
Sertraline Hcl	Sertraline Hcl	32	13
Meclizine Hcl	Meclizine Hcl	31	13
Famotidine	Famotidine	30	13
Hydralazine Hcl	Hydralazine Hcl	29	11
Pioglitazone Hcl	Pioglitazone Hcl	29	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	28	suppressed
Pregabalin	Pregabalin	28	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	27	suppressed
Tizanidine Hcl	Tizanidine Hcl	27	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	25	11
Mirtazapine	Mirtazapine	25	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	25	suppressed
Azithromycin	Azithromycin	24	21
Clonidine Hcl	Clonidine Hcl	24	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	24	suppressed
Ezetimibe	Ezetimibe	24	suppressed
Glyxambi	Empagliflozin/Linagliptin	24	suppressed
Meloxicam	Meloxicam	24	13
Montelukast Sodium	Montelukast Sodium	24	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	23	suppressed
Bupropion Xl	Bupropion Hcl	21	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	21	suppressed
Mounjaro	Tirzepatide	19	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	18	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	16
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	18	suppressed
Duloxetine Hcl	Duloxetine Hcl	18	suppressed
Ibuprofen	Ibuprofen	18	suppressed
Breo Ellipta	Fluticasone/Vilanterol	17	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	17	suppressed
Methylprednisolone	Methylprednisolone	17	suppressed
Benazepril Hcl	Benazepril Hcl	16	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	16	suppressed
Jentadueto	Linagliptin/Metformin Hcl	16	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Valsartan	Valsartan	16	suppressed
Xarelto	Rivaroxaban	16	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Celecoxib	Celecoxib	15	suppressed
Colchicine	Colchicine	15	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	14	suppressed
Baclofen	Baclofen	14	suppressed
Enalapril Maleate	Enalapril Maleate	14	suppressed
Estradiol	Estradiol	14	suppressed
Folic Acid	Folic Acid	14	suppressed
Januvia	Sitagliptin Phosphate	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Methimazole	Methimazole	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Warfarin Sodium	Warfarin Sodium	14	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Topiramate	Topiramate	13	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Alprazolam	Alprazolam	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Insulin Aspart Flexpen	Insulin Aspart	12	suppressed
Ramipril	Ramipril	12	suppressed
Tamoxifen Citrate	Tamoxifen Citrate	12	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Ventolin Hfa	Albuterol Sulfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error